Linda Beer, PhD, on Cost as a Barrier to ART Adherence
02/27/2020
In this podcast, Linda Beer, PhD, from the Centers for Disease Control and Prevention, talks about her team's latest analysis of US surveillance data of adults with HIV infection that examined the financial barriers to antiretroviral therapy adherence.
Linda Beer, PhD, is an epidemiologist in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention in Atlanta, Georgia.
Additional Resources:
- Beer L, Tie Y, Weiser J, Shouse RL. Nonadherence to any prescribed medication due to costs among adults with HIV infection - United States, 2016-2017. MMWR Morb Mortal Wkly Rep. 2019;68(49):1129-1133. https://doi.org/10.15585/mmwr.mm6849a1.
- Ending the HIV Epidemic: A Plan for America. Centers for Disease Control and Prevention. Reviewed February 3, 2020. Accessed February 6, 2020. https://www.cdc.gov/endhiv/index.html.
- American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Department of Health and Human Services. Published May 2018. Accessed February 6, 2020. https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf.
- Alexander L. S. 1895: Lower Health Care Costs Act. GovTrack. Updated July 9, 2019. Accessed February 6, 2020. https://www.govtrack.us/congress/bills/116/s1895.
- Medical Monitoring Project (MMP). Centers for Disease Control and Prevention. Reviewed October 2, 2019. Accessed February 7, 2020. https://www.cdc.gov/hiv/statistics/systems/mmp/index.html.
